Concepedia

A Phase I Study of Weekly R1507, A Human Monoclonal Antibody Insulin-like Growth Factor-I Receptor Antagonist, in Patients with Advanced Solid Tumors

Razelle Kurzrock, Amita Patnaik, Joseph Aisner, Terri Warren, Stephen Leong, Robert S. Benjamin, Sabine Eckhardt, Joseph Eid, Gérard Greig, Kai Habben,

Clinical Cancer Research · 2010 · 194 citations · 29 references

DOI

Abstract

R1507 is well tolerated and shows antitumor activity in patients with solid neoplasms, in particular Ewing's sarcoma. The recommended dose for the weekly schedule is 9 mg/kg qW.

References

29

New Guidelines to Evaluate the Response to Treatment in Solid Tumors

Patrick Therasse, Susan G. Arbuck, Elizabeth A. Eisenhauer et al. · JNCI Journal of the National Cancer Institute · 2000 · 15.7K citations

, , +17

Plasma Insulin-Like Growth Factor-I and Prostate Cancer Risk: A Prospective Study

June M. Chan, Meir J. Stampfer, Edward L. Giovannucci et al. · Science · 1998 · 2K citations

Prospective Study of Colorectal Cancer Risk in Men and Plasma Levels of Insulin-Like Growth Factor (IGF)-I and IGF-Binding Protein-3

Jianchao Ma, Michaël Pollak, E. Giovannucci et al. · JNCI Journal of the National Cancer Institute · 1999 · 1.1K citations · Full text

Insulin-Like Growth Factor-I (IGF-I) and IGF Binding Protein-3 as Predictors of Advanced-Stage Prostate Cancer

June M. Chan · JNCI Journal of the National Cancer Institute · 2002 · 436 citations · Full text

EWS/FLI-1 Silencing and Gene Profiling of Ewing Cells Reveal Downstream Oncogenic Pathways and a Crucial Role for Repression of Insulin-Like Growth Factor Binding Protein 3

Alexandre Prieur, Franck Tirode, Pinchas Cohen et al. · Molecular and Cellular Biology · 2004 · 415 citations · Full text

, , +13